Onkolojik Tedaviye Bağlı Arteriyel Hipertansiyon

Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib refractory metastatic renal cell carcinoma. J Clin Oncol. 2009;27:444-448.

Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesisinhibitor-treatedpatients. AnnOncol 2009;20: 807–15.

Fraeman KH, Nordstrom BL, Luo W, Landis SH, Shantakumar S. Incidence of new-onsethypertension in cancerpatients: a retrospectivecohortstudy. Int J Hypertens 2013;2013:379252.

Folkman J. Tumorangiogenesis: Therapeuticimplications. N Eng J Med. 1971; 285(21):1182-6

Ferrara N, Houck K, Jakeman L, Leung DW. Molecularandbiologicalproperties of thevascularendothelialgrowthfactorfamily of proteins. EndocrRev. 1992;13(1):18-32

Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulatesecNOSmessage, protein, and NO production in humanendothelialcells. Am J Physiol 1998;274:H1054–8.

Madeddu P. Therapeuticangiogenesisandvasculogenesisfortissueregeneration. ExpPhysiol 2005;90:315–26.

Pandey AK, Singhi EK, Arroyo JP, et al. Mechanisms of VEGF (vascularendothelialgrowthfactor) inhibitor-associatedhypertensionandvasculardisease. Hypertension 2018;71:e1–8

Lankhorst S, Danser AH, van den Meiracker AH. Endothelin-1 andantiangiogenesis. Am J PhysiolRegulIntegrCompPhysiol 2016;310:R230–4.

Vigneau C, Lorcy N, Dolley-Hitze T, et al. All anti-vascularendothelialgrowthfactordrugs can induce ’pre-eclampsia-likesyndrome’: a RARestudy. Nephrol Dial Transplant 2014;29:325–32.

Totzeck M, Mincu RI, Mrotzek S, Schadendorf D, Rassaf T. Cardiovasculardiseases in patientsreceivingsmallmoleculeswithantivascularendothelialgrowthfactoractivity: a meta-analysis of approximately 29,000 cancerpatients. Eur J PrevCardiol 2018;25:482–94

Abdel-Qadir H, Ethier JL, Lee DS, Thavendiranathan P, Amir E. Cardiovasculartoxicity of angiogenesisinhibitors in treatment of malignancy: a systematicreviewandmetaanalysis. CancerTreatRev 2017;53:120–7.

Corrie PG. Cytotoxic chemotherapy: clinicalaspects. Medicine 2008;36(1):24-28.

Talcott JA, Herman TS. Acute ischemicvasculareventsandcisplatin. AnnInternMed 1987;107:121–2.

Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamidecardiotoxicity in bone marrowtransplantation: a prospectiveevaluation of newdosingregimens. J ClinOncol 1991;9:1215–23.

Al-Hashmi S, Boels PJ, Zadjali F, et al. Busulphan-cyclophosphamidecauseendothelialinjury, remodeling of resistancearteriesandenhancedexpression of endothelialnitricoxidesynthase. PLoSOne 2012;7:e30897.

Ben VenueLaboratories. BusulfexTM: (BusulfanInjection) [package insert]. RevisedFebruary 10, 1999. U.S. FoodandDrug Administration website. Available at: https://www.accessdata.fda.gov/ drugsatfda_docs/label/1999/20954lbl.pdf. AccessedJuly 15, 2019.

Socie G, Clift RA, Blaise D, et al. Busulfanpluscyclophosphamidecomparedwith total-body irradiationpluscyclophosphamidebeforemarrowtransplantationformyeloidleukemia: long-termfollow-up of 4 randomizedstudies. Blood 2001; 98:3569–74.

Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomizedstudy of bendamustinecomparedwithchlorambucil in previouslyuntreatedpatientswithchroniclymphocyticleukemia. J ClinOncol 2009;27:4378–84.

Skinner R, Cotterill SJ, Stevens MC, United KingdomChildren’sCancerStudyGroup. Risk factorsfornephrotoxicityafterifosfamidetreatment in children: a UKCCSG LateEffectsGroupstudy. Br J Cancer 2000;82:1636–45.

McMahon KR, Harel-Sterling M, Pizzi M, Huynh L, Hessey E, Zappitelli M. Long-termrenalfollow-up of childrentreatedwithcisplatin, carboplatin, orifosfamide: a pilot study. Pediatr Nephrol 2018;33:2311–20.

Dursun B, He Z, Somerset H, Oh DJ, Faubel S, Edelstein CL. Caspasesandcalpainareindependentmediators of cisplatin-inducedendothelialcellnecrosis. Am J PhysiolRenalPhysiol 2006; 291:F578–87.

McLucas E, Gallagher H, Rochev Y, Carroll WM, Gorelov A, Smith TJ. Global gene expressionanalysis of theeffects of vinblastine on endothelialcells, whenelutedfrom a thermo-responsivepolymer. J Biomed Mater Res A 2006;79:246–53.

Stoter G, Koopman A, Vendrik CP, et al. Tenyearsurvivalandlatesequelae in testicularcancerpatientstreatedwithcisplatin, vinblastine, andbleomycin. J ClinOncol 1989;7:1099–104.

vanHell AJ, Haimovitz-Friedman A, Fuks Z, Tap WD, Kolesnick R. Gemcitabinekillsproliferatingendothelialcellsexclusivelyviaacidsphingomyelinaseactivation. Cell Signal 2017;34: 86–91.

Shah C, Bishnoi R, Jain A, et al. Cardiotoxicityassociatedwithcarfilzomib: systematicreviewand meta-analysis. LeukLymphoma 2018;59:2557–69.

Yui JC, Van Keer J, Weiss BM, et al. Proteasome inhibitor associatedthromboticmicroangiopathy. Am J Hematol 2016;91:E348–52.

Fakhouri F, La Batide Alanore A, Rerolle JP, Guery B, Raynaud A, Plouin PF. Presentation andrevascularizationoutcomes in patientswithradiation-inducedrenalarterystenosis. Am J KidneyDis 2001;38:302–9.

Sharabi Y, Dendi R, Holmes C, Goldstein DS. Baroreflexfailure as a latesequela of neckirradiation. Hypertension 2003;42:110–6.

Tonia T, Mettler A, Robert N, et al. Erythropoietinordarbepoetinforpatientswithcancer. Cochrane Database SystRev 2012;1 2: CD003407.

Hoskova L, Malek I, Kopkan L, Kautzner J. Pathophysiologicalmechanisms of calcineurininhibitor-inducednephrotoxicityandarterialhypertension. PhysiolRes 2017;66:167–80.

Muntner P, Einhorn PT, Cushman WC, et al. Blood pressureassessment in adults in clinicalpracticeandclinic-basedresearch: JACC scientificexpert panel. J AmCollCardiol 2019;73:317–35.

Kallioinen N, Hill A, Horswill MS, Ward HE, Watson MO. Sources of inaccuracy in themeasurement of adultpatients’ restingbloodpressure in clinicalsettings: a systematicreview. J Hypertens 2017;35:421–41.

Muntner P, Shimbo D, Carey RM, et al. Measurement of bloodpressure in humans: a scientificstatementfromtheAmericanHeartAssociation. Hypertension 2019;73:e35–66. 71.

Cohen JB, Lotito MJ, Trivedi UK, Denker MG, Cohen DL, Townsend RR. Cardiovasculareventsandmortality in White coathypertension: a systematicreviewand meta-analysis. AnnInternMed 2019;170:853–62.

Pierdomenico SD, Pierdomenico AM, Coccina F, et al. Prognosticvalue of maskeduncontrolledhypertension. Hypertension 2018;72: 862–9.

Bamias A, Manios E, Karadimou A, et al. Theuse of 24-h ambulatorybloodpressuremonitoring (ABPM) duringthefirstcycle of sunitinibimprovesthediagnosticaccuracyandmanagement of hypertension in patientswithadvancedrenalcancer. Eur J Cancer 2011;47:1660–8.

Zamorano JL, Lancellotti P, RodriguezMunoz D, et al. 2016 ESC positionpaper on cancertreatmentsandcardiovasculartoxicitydevelopedundertheauspices of the ESC CommitteeforPracticeGuidelines: theTask Force forcancertreatmentsandcardiovasculartoxicity of theEuropeanSociety of Cardiology (ESC). EurHeart J 2016;37:2768–801.

Kronish IM, Kent S, Moise N, et al. Barrierstoconductingambulatoryandhomebloodpressuremonitoringduringhypertensionscreening in the United States. J AmSocHypertens 2017;11: 573–80.

AmericanHeartAssociationandAmericanMedicalAssociation. Tools &Downloads. RevisedJuly 25, 2019. Target:BPwebsite. Available at: AccessedJuly 28, 2019.

Wright JT Jr,Williamson JD, Whelton PK, et al., SPRINT ResearchGroup. A randomizedtrial of intensiveversusstandardblood-pressurecontrol. N Engl J Med 2015;373:2103–16.

Cushman WC, Evans GW, Byington RP, et al., ACCORD StudyGroup. Effects of intensivebloodpressurecontrol in type 2 diabetesmellitus. N Engl J Med 2010;362:1575–85.

Agarwal M, Thareja N, Benjamin M, Akhondi A, Mitchell GD. Tyrosinekinaseinhibitor-inducedhypertension. CurrOncolRep 2018;20:65.

Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focusedupdate of the 2013 ACCF/ AHA guidelineforthemanagement of heartfailure: a report of theAmericanCollege of Cardiology/AmericanHeartAssociationTask Force on ClinicalPracticeGuidelinesandtheHeartFailureSociety of America. Circulation 2017;136:e137–61.

Li XY, Sun JF, Hu SQ. The renin-angiotensinsystemblockers as adjunctivetherapyforcancer: a meta-analysis of survivaloutcome. EurRevMedPharmacolSci 2017;21:1375–83.

Leenen FH, Nwachuku CE, Black HR, et al. Clinicalevents in high-risk hypertensivepatientsrandomlyassignedtocalciumchannelblockerversusangiotensin-convertingenzymeinhibitor in theantihypertensiveandlipid-loweringtreatmenttopreventheartattacktrial. Hypertension 2006;48:374–84.

Wright JT Jr.,Dunn JK, Cutler JA, et al. Outcomes in hypertensiveblackandnonblackpatientstreatedwithchlorthalidone, amlodipine, andlisinopril. JAMA 2005;293:1595–608.

Doerfler RM, Diamantidis CJ, Wagner LA, et al. Usabilitytesting of a sick-dayprotocol in CKD. Clin J AmSocNephrol 2019;14:583–5.

Carey RM, Calhoun DA, Bakris GL, et al. Resistanthypertension: detection, evaluation, andmanagement: a scientificstatementfromtheAmericanHeartAssociation. Hypertension 2018; 72:e53–90.

Sacco M, Meschi M, Regolisti G, et al. Therelationshipbetweenbloodpressureandpain. J ClinHypertens (Greenwich) 2013;15:600–5.